Ontology highlight
ABSTRACT:
SUBMITTER: Pott C
PROVIDER: S-EPMC7214251 | biostudies-literature | 2020 Feb
REPOSITORIES: biostudies-literature
Leukemia 20190828 2
We report assessment of minimal residual disease (MRD) status and its association with outcome in rituximab-refractory follicular lymphoma (FL) in the randomized GADOLIN trial (NCT01059630). Patients received obinutuzumab (G) plus bendamustine (Benda) induction followed by G maintenance, or Benda induction alone. Patients with a clonal marker (t[14;18] translocation and/or immunoglobulin heavy or light chain rearrangement) detected at study screening were assessed for MRD at mid-induction (MI), ...[more]